查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030002

胚胎著床前基因檢測市場－全球產業規模、佔有率、趨勢、機會、預測：依流程、產品、技術、應用、最終用戶、區域和競爭格局分類，2021-2031年

Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure, By Product, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胚胎著床前基因檢測 (PGT) 市場預計將從 2025 年的 6.6067 億美元成長到 2031 年的 10.6954 億美元，複合年成長率為 8.36%。

PGT（妊娠指導檢測）是指在體外受精產生的胚胎植入子宮前，對其染色體異常和特定單基因疾病進行分析的過程。該市場的成長主要受全球人口結構變化所驅動，例如母親平均年齡的成長，這增加了遺傳缺陷的風險；此外，輔助生殖技術的不斷進步也提高了PGT的有效性。根據歐洲人類生殖與胚胎學會（ESHRE）PGT聯盟的數據，2023年參與機構共記錄了約9971個PGT切片檢查週期。

市場概覽
預測期 2027-2031
市場規模：2025年 6.6067億美元
市場規模：2031年 1,069,540,000 美元
複合年成長率：2026-2031年 8.36%
成長最快的細分市場 聚合酵素鏈鎖反應（PCR）
最大的市場 歐洲

此外，臨床醫生和患者對最大限度減少遺傳疾病傳播益處的認知不斷提高，正在推動市場成長。然而，市場成長的主要障礙包括胚胎胚胎著床前遺傳學檢測（PGT）的高昂費用，以及不同醫療保健系統保險覆蓋範圍不足或不完善，這些都可能阻礙該技術的廣泛應用。

市場促進因素

基因檢測技術的進步是全球胚胎著床前遺傳學檢測 (PGT) 市場的主要驅動力，使得胚胎評估更加精準全面。定序技術的持續發展，尤其是次世代定序(NGS) 技術，提高了對特定單基因疾病和染色體異常的辨識準確性。例如，2023 年 7 月，賽默飛世爾科技公司發布了兩款基於 NGS 的全新檢測解決方案：Ion AmpliSeq 多倍體檢測試劑盒和 Ion ReproSeq PGT-A 檢測試劑盒，這兩款試劑盒專為支持胚胎胚胎著床前染色體數目異常檢測而設計。這些突破性進展提升了 PGT 流程的可靠性和效率，拓寬了其應用範圍，並增強了準父母和醫療專業人員的信心。

全球不孕症的激增進一步推動了胚胎胚胎著床前遺傳學檢測（PGT）市場的發展，增加了對輔助生殖技術的需求，而PGT通常也是輔助生殖技術的重要組成部分。隨著越來越多的個人和夫婦接受生育治療，對胚胎遺傳篩檢的需求日益成長，以提高懷孕成功率並降低遺傳疾病的風險。 2023年4月，世界衛生組織（WHO）報告稱，全球約有17.5%的成年人面臨不孕症問題。這是一個普遍存在的挑戰，加速了體外受精（IVF）的普及，並擴大了PGT患者群體。因此，隨著PGT日益成為旨在最佳化胚胎移植結果的生育治療中的標準組成部分，市場正在不斷擴張。根據歐洲人類生殖與胚胎學會（ESHRE）歐洲IVF監測聯盟於2024年3月發布的初步數據，2021年歐洲37個國家共進行了1,103,633個輔助生殖技術（ART）週期。

市場挑戰

全球胚胎著床前遺傳學檢測（PGT）市場成長的主要障礙在於PGT流程的高昂費用，以及不同醫療體系中保險報銷機制的不完善或不規範。這一經濟壁壘嚴重限制了市場擴張，使得許多潛在患者難以負擔PGT。儘管PGT在檢測遺傳缺陷方面已展現出臨床優勢，但高昂的自付費用，加上體外受精週期本身就已十分昂貴，阻礙了人們選擇PGT。

由於缺乏全球統一、全面的保險報銷機制，未來父母的經濟不確定性增加，阻礙了胚胎植入前遺傳學檢測（PGT）的廣泛應用。在PGT保險涵蓋不足的地區，患者必須承擔全部費用，而這些費用往往十分昂貴。根據CARE生育與婦女健康中心的數據，到2025年，在美國，針對染色體異常的胚胎胚胎著床前遺傳學檢測（PGT-A）每個週期的費用將在2500美元至4000美元之間，而針對單基因疾病的更複雜的檢測（PGT-M）每個週期的費用將在7000美元至12000美元之間。如此高昂的費用通常不在綜合保險的報銷範圍內，迫使許多患者放棄這些先進的基因篩檢，阻礙了胚胎著床前遺傳學檢測服務的全球成長和市場擴張。

市場趨勢

人工智慧（AI）在胚胎評估中的應用正顯著改變著全球胚胎著床前遺傳學檢測（PGT）市場，為胚胎選擇過程帶來更高的精準度和客觀性。這一趨勢超越了傳統的形態學評估，利用複雜的演算法處理源自胚胎測量數據和延時成像的複雜數據。這最大限度地減少了人為偏見，並提高了評估的一致性。如同2025年12月發表於《生殖生物學與內分泌學》雜誌的綜述文章「人工智慧在常規體外受精實踐中的應用」中所述，研究表明，與標準胚胎學家評估相比，人工智慧系統在預測胚胎活力和著床成功率方面可將準確率提高10%至25%。這種準確率的提高使得單一胚胎移植更加可靠，並最大限度地提高了體外受精的成功率，從而增強了患者和醫療保健提供者對PGT的信心。

另一個重要趨勢是非侵入性胚胎著床前遺傳學檢測（niPGT）的日益普及，旨在降低與侵入性切片檢查相關的胚胎潛在風險。 niPGT透過評估釋放到胚胎培養基中的遊離DNA，避免了滋養層切片檢查的必要性。這項技術因其簡化檢查室流程並減輕胚胎的生理負擔而備受關注。 2025年10月發表於《生殖科學》（Reproductive Sciences）雜誌的一項題為“最佳化無創PGT-A：提高準確性並無縫整合到臨床IVF中的多因素方法”的研究表明，改進後的niPGT-A流程展現出令人矚目的91.3%的準確率和92.1%的陽性預測率，超越了傳統PG-A的流程。這些進展對於市場拓展至關重要，因為它們在提高診斷可靠性的同時，也緩解了安全性和倫理方面的擔憂。

目錄

第1章 產品概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胚胎著床前基因檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 基於程序的（胚胎著床前遺傳篩檢、胚胎著床前遺傳診斷）
    • 產品類別（試劑及耗材、儀器、軟體）
    • 依技術（次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、螢光雜合反應（FISH）等）
    • 依應用領域（染色體異常、X連鎖疾病、胚胎檢測、非整倍體篩檢、 HLA型檢測等）
    • 按最終使用者（不孕症治療中心、醫院、診斷中心、研究中心、大學研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胚胎著床前基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胚胎著床前基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區胚胎著床前基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲胚胎著床前基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲胚胎著床前基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球胚胎著床前基因檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sutter Health
  • Acacia Research Corporation
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche AG
  • Genea Pty Limited
  • Genesis Genetics
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Illumina, Inc.
  • Natera, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 13099

The Global Preimplantation Genetic Testing Market is anticipated to expand from USD 660.67 Million in 2025 to USD 1069.54 Million by 2031, registering an 8.36% CAGR. PGT involves analyzing embryos generated via in vitro fertilization for chromosomal irregularities and specific monogenic conditions before they are transferred to the uterus. This market growth is largely fueled by changing global demographics, such as the increasing average age of mothers, which elevates the risk of genetic defects, alongside ongoing improvements in assisted reproductive technologies that boost PGT effectiveness. Data from the European Society of Human Reproduction and Embryology PGT Consortium indicates that participating centers recorded around 9,971 PGT biopsy cycles in 2023.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 660.67 Million
Market Size 2031USD 1069.54 Million
CAGR 2026-20318.36%
Fastest Growing SegmentPolymerase Chain Reaction (PCR)
Largest MarketEurope

Furthermore, the market is being stimulated by growing awareness among both clinicians and patients about the advantages of minimizing the transmission of hereditary genetic diseases. Nevertheless, a major obstacle to market growth continues to be the hefty expenses tied to PGT procedures, coupled with inadequate or irregular insurance coverage across diverse healthcare systems, which could impede wider acceptance of the technology.

Market Driver

Progress in genetic testing technology acts as a primary catalyst for the global Preimplantation Genetic Testing market, facilitating more exact and thorough embryo assessments. The ongoing development of sequencing methods, especially Next-Generation Sequencing, yields greater precision in identifying specific monogenic conditions and chromosomal anomalies. To illustrate, Thermo Fisher Scientific introduced two novel NGS-based research solutions in July 2023-the Ion AmpliSeq Polyploidy Kit and the Ion ReproSeq PGT-A Kit-tailored to assist with preimplantation genetic testing for aneuploidy. Such breakthroughs enhance the dependability and efficiency of PGT processes, broadening their usage and building higher trust among prospective parents and healthcare professionals.

A surge in global infertility rates further drives the Preimplantation Genetic Testing market by heightening the need for assisted reproductive technologies that frequently incorporate PGT. With an increasing number of individuals and couples undergoing fertility therapies, the demand for embryonic genetic screening grows to elevate pregnancy success and mitigate genetic disease risks. The World Health Organization reported in April 2023 that roughly 17.5% of adults worldwide face infertility issues, a pervasive challenge that accelerates IVF adoption and broadens the PGT patient base. As a result, the market expands as PGT becomes an increasingly standard element of fertility treatments designed to optimize embryo transfer outcomes. Preliminary figures from the European Society of Human Reproduction and Embryology's European IVF Monitoring Consortium, shared in March 2024, noted 1,103,633 Assisted Reproductive Technology cycles across 37 European nations during 2021.

Market Challenge

A major obstacle hindering the growth of the Global Preimplantation Genetic Testing Market is the steep expense of PGT processes, combined with sparse or irregular insurance reimbursement frameworks across diverse healthcare infrastructures. This monetary hurdle actively curbs market expansion by rendering PGT unaffordable for a large portion of prospective patients. The burden of heavy out-of-pocket costs, paired with the already expensive nature of in vitro fertilization rounds, discourages people from utilizing PGT even with its proven clinical advantages in detecting genetic defects.

The absence of uniform and inclusive reimbursement frameworks internationally adds to the financial unpredictability for future parents, impeding widespread utilization. In regions lacking sufficient PGT coverage, patients must shoulder the entire, often prohibitive, financial load. Data from CARE Fertility and Women's Health indicates that by 2025, Preimplantation Genetic Testing for Aneuploidy (PGT-A) in the United States reached between $2,500 and $4,000 per cycle, while more intricate assessments for single gene conditions (PGT-M) cost between $7,000 and $12,000 per cycle. These steep fees, frequently left out of comprehensive insurance plans, compel numerous patients to skip these sophisticated genetic screenings, ultimately restricting the worldwide growth and market reach of preimplantation genetic testing services.

Market Trends

The incorporation of Artificial Intelligence into embryo evaluation is dramatically transforming the Global Preimplantation Genetic Testing Market by bringing greater accuracy and objectivity to the embryo selection process. Moving past conventional morphological assessments, this trend utilizes sophisticated algorithms to process intricate data from embryological metrics and time-lapse imagery, which minimizes human bias and elevates grading consistency. Research indicates that AI systems offer a 10 to 25% improvement in accuracy when forecasting embryo survivability and implantation success compared to standard embryologist evaluations, as noted in a December 2025 review in Reproductive Biology and Endocrinology titled 'Artificial Intelligence in Routine IVF Practice'. Such heightened precision encourages more assured single-embryo transfers and maximizes in vitro fertilization success, strengthening trust in PGT among both patients and healthcare providers.

Another crucial trend is the growing utilization of non-invasive preimplantation genetic testing (niPGT), motivated by the goal of reducing the potential embryonic risks linked to invasive biopsies. By evaluating cell-free DNA discharged into the culture medium of the embryo, niPGT bypasses the necessity for a trophectoderm biopsy. This technique is gaining traction because it lowers physical strain on embryos while streamlining laboratory procedures. According to an October 2025 study in Reproductive Sciences titled 'Optimizing Non-Invasive PGT-A: A Multi-Factorial Approach for Enhanced Accuracy and Seamless Integration Into Clinical IVF', a refined niPGT-A process demonstrated a remarkable 91.3% accuracy and a 92.1% Positive Predictive Value, exceeding traditional PGT-A metrics. These developments are essential for expanding market reach, as they improve diagnostic trustworthiness while alleviating safety and ethical worries.

Key Market Players

  • Sutter Health
  • Acacia Research Corporation
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche AG
  • Genea Pty Limited
  • Genesis Genetics
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Natera, Inc.

Report Scope

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preimplantation Genetic Testing Market, By Procedure

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Preimplantation Genetic Testing Market, By Product

  • Reagents and Consumables
  • Instruments
  • Software

Preimplantation Genetic Testing Market, By Technology

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Others

Preimplantation Genetic Testing Market, By Application

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other

Preimplantation Genetic Testing Market, By End User

  • Fertility Centers
  • Hospitals
  • Diagnostic Centers
  • Research Centers
  • Academic Labs

Preimplantation Genetic Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

Global Preimplantation Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preimplantation Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis)
    • 5.2.2. By Product (Reagents and Consumables, Instruments, Software)
    • 5.2.3. By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others)
    • 5.2.4. By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other)
    • 5.2.5. By End User (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers, Academic Labs)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Preimplantation Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Procedure
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preimplantation Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Procedure
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Preimplantation Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Procedure
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Preimplantation Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Procedure
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Preimplantation Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Procedure
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preimplantation Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Procedure
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Preimplantation Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Procedure
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Preimplantation Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Procedure
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Preimplantation Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Procedure
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Preimplantation Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Procedure
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Preimplantation Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Procedure
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Preimplantation Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Procedure
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Preimplantation Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Procedure
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Preimplantation Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Procedure
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Preimplantation Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Procedure
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Preimplantation Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Procedure
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Preimplantation Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Procedure
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Preimplantation Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Procedure
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Preimplantation Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Procedure
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Preimplantation Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Procedure
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Preimplantation Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Procedure
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Preimplantation Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Procedure
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Preimplantation Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Procedure
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Preimplantation Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Procedure
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Preimplantation Genetic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sutter Health
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Acacia Research Corporation
  • 15.3. CooperSurgical, Inc.
  • 15.4. F. Hoffmann-La Roche AG
  • 15.5. Genea Pty Limited
  • 15.6. Genesis Genetics
  • 15.7. Thermo Fisher Scientific Inc.
  • 15.8. QIAGEN N.V.
  • 15.9. Illumina, Inc.
  • 15.10. Natera, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer